' 
![]()
SCIENTIFIC SCORE
Moderately Effective
Based on 13 Researches
8.4
USERS' SCORE
Good
Based on 1 Review
8.4
Supplement Facts
Serving Size: 31 g (About 1 Scoop)
Amount Per Serving
%DV
Calories
120
Total Fat
1.5 g
2%
Saturated Fat
1 g
5%
Cholesterol
60 mg
20%
Sodium
130 mg
6%
Total Carbohydrate
3 g
1%
Total Sugars
2 g
Protein
24 g
48%
Calcium
140 mg
10%
Potassium
150 mg
4%
Top Medical Research Studies
9
Gracillin shows promise against cancer
Gracillin suppresses cancer progression through inducing Merlin/LATS protein-protein interaction and activating Hippo signaling pathway.
High relevance to breast cancer
We investigated the potential of gracillin, a natural saponin derived from herbs, as a treatment for breast cancer and other malignancies. In our research, gracillin demonstrated significant ability to slow down the growth of breast cancer cells, liver cancer cells, and glioblastoma cells. The experiments showed that gracillin effectively inhibited cell proliferation, migration, and invasion at concentrations around 1 μM.
This natural compound works by activating the Hippo signaling pathway in a unique way. We found that gracillin enhances the interaction between two proteins, Merlin and LATS, which is crucial for activating this pathway. Disrupting this interaction with a specific peptide negated gracillin's anticancer effects, highlighting its importance in our findings.
Additionally, we conducted tests on nude mice with breast cancer tumors. The administration of gracillin resulted in a noticeable reduction in tumor growth, correlating with the induced protein interactions and the activated Hippo signaling. Our results underscore the promise of gracillin as a potential therapeutic agent in cancer treatment, particularly through its novel approach to activating crucial signaling pathways.
This natural compound works by activating the Hippo signaling pathway in a unique way. We found that gracillin enhances the interaction between two proteins, Merlin and LATS, which is crucial for activating this pathway. Disrupting this interaction with a specific peptide negated gracillin's anticancer effects, highlighting its importance in our findings.
Additionally, we conducted tests on nude mice with breast cancer tumors. The administration of gracillin resulted in a noticeable reduction in tumor growth, correlating with the induced protein interactions and the activated Hippo signaling. Our results underscore the promise of gracillin as a potential therapeutic agent in cancer treatment, particularly through its novel approach to activating crucial signaling pathways.
Read More
9
MA242 shows promise against breast cancer
Dual inhibitor of MDM2 and NFAT1 for experimental therapy of breast cancer: and anticancer activities and newly discovered effects on cancer metabolic pathways.
High relevance to breast cancer treatment
We explored how MA242, a dual inhibitor targeting MDM2 and NFAT1, could change the game in treating breast cancer. Our study used a variety of breast cancer cell lines with different p53 backgrounds and involved advanced models to see the true impact of this new treatment.
The results were promising. We observed that MA242 effectively reduced cell viability and triggered apoptosis, or programmed cell death, in breast cancer cells—regardless of whether they had the p53 protein. This means it might be effective even in cases where traditional therapies fall short.
Furthermore, we found that MA242 disrupts important metabolic processes within cancer cells, particularly around nicotinamide and nucleotide metabolism, while also increasing oxidative stress. In animal models, it successfully inhibited tumor growth linked to MDM2 expression without harmful side effects, which is a significant advantage.
Overall, our findings suggest that MA242 holds great potential as a treatment option for aggressive breast cancers by modulating cancer metabolism. We believe this dual approach could lead to more effective therapies, especially for patients who have limited options today.
The results were promising. We observed that MA242 effectively reduced cell viability and triggered apoptosis, or programmed cell death, in breast cancer cells—regardless of whether they had the p53 protein. This means it might be effective even in cases where traditional therapies fall short.
Furthermore, we found that MA242 disrupts important metabolic processes within cancer cells, particularly around nicotinamide and nucleotide metabolism, while also increasing oxidative stress. In animal models, it successfully inhibited tumor growth linked to MDM2 expression without harmful side effects, which is a significant advantage.
Overall, our findings suggest that MA242 holds great potential as a treatment option for aggressive breast cancers by modulating cancer metabolism. We believe this dual approach could lead to more effective therapies, especially for patients who have limited options today.
Read More
9
Immuno-PET detects lymph node cancer
Preclinical evaluation of Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer.
Significantly relevant to breast cancer
We tackled the challenge of detecting sentinel lymph node (SLN) metastasis in breast cancer, particularly focusing on cases with epidermal growth factor receptor (EGFR) positivity. By utilizing a specific model that involved the MDA-MB-468 breast cancer cell line, we tested the effectiveness of Cu-labeled cetuximab, a protein treatment, through a method known as immuno-positron emission tomography (immuno-PET).
In our experiments, we introduced [Cu]Cu-PCTA-cetuximab into the body either intravenously or via local injections around the tumor. Following this, we conducted imaging with PET to gauge how well this treatment could pinpoint the presence of cancer in SLNs. Importantly, our findings indicated that the intravenously administered Cu-labeled cetuximab was particularly effective in diagnosing SLN metastasis.
Furthermore, the method showed promise for better detection of cancerous spread compared to conventional approaches. Although we still need more research, the idea of applying this treatment through local injections appears beneficial, highlighting its focused accumulation in the lymph nodes.
In our experiments, we introduced [Cu]Cu-PCTA-cetuximab into the body either intravenously or via local injections around the tumor. Following this, we conducted imaging with PET to gauge how well this treatment could pinpoint the presence of cancer in SLNs. Importantly, our findings indicated that the intravenously administered Cu-labeled cetuximab was particularly effective in diagnosing SLN metastasis.
Furthermore, the method showed promise for better detection of cancerous spread compared to conventional approaches. Although we still need more research, the idea of applying this treatment through local injections appears beneficial, highlighting its focused accumulation in the lymph nodes.
Read More
Most Useful Reviews
7.5
Protein benefits highlight
#1 product on the market! I'm a Certified Master Trainer with over 20 years of experience, and I use Whey Protein Isolate daily. Specifically, I swear by Optimum Nutrition 100% Whey Gold Standard because it offers great protein concentration and minimal lactose. It's crucial for muscle and immune health, and it even helps reduce the risk of breast cancer in women. The taste is phenomenal, and it mixes well, ensuring I get the nutrition I need to stay fit and healthy.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 13 Researches
8.4
9
Multimodal strategy against breast cancer
Reprogrammed glycolysis-induced augmentation of NIR-II excited photodynamic/photothermal therapy.
Effective combination cancer treatment
We explored an innovative approach to breast cancer treatment that combines photodynamic therapy (PDT), photothermal therapy (PTT), and a mitochondrial disruption strategy using a specially engineered compound. This strategy employs a multifaceted photosensitizer called PPQ-CTPA, which effectively generates reactive oxygen species and heat when activated by a near-infrared laser at 1064 nm.
To further boost the effects of this therapy, we utilized a conjugate called LND-TPP, designed to inhibit a specific cellular process known as mitochondrial glycolysis and reduce the levels of heat shock protein 90. When tested in breast cancer mouse models, this combination of therapies demonstrated a significant ability to restrain tumor growth. The treatment method involves encapsulating both PPQ-CTPA and LND-TPP within a polymer to ensure these agents are delivered efficiently to cancer cells.
The results indicate that the therapy not only integrates different treatment modalities but also highlights the potential of using NIR-II imaging to track treatment progress. By releasing the active components in response to cellular conditions, we observed a synergistic effect that enhances the overall efficacy of breast cancer treatment. This multifaceted approach shows promise as we look toward future applications in clinical settings.
To further boost the effects of this therapy, we utilized a conjugate called LND-TPP, designed to inhibit a specific cellular process known as mitochondrial glycolysis and reduce the levels of heat shock protein 90. When tested in breast cancer mouse models, this combination of therapies demonstrated a significant ability to restrain tumor growth. The treatment method involves encapsulating both PPQ-CTPA and LND-TPP within a polymer to ensure these agents are delivered efficiently to cancer cells.
The results indicate that the therapy not only integrates different treatment modalities but also highlights the potential of using NIR-II imaging to track treatment progress. By releasing the active components in response to cellular conditions, we observed a synergistic effect that enhances the overall efficacy of breast cancer treatment. This multifaceted approach shows promise as we look toward future applications in clinical settings.
Read More
9
Immuno-PET detects lymph node cancer
Preclinical evaluation of Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer.
Significantly relevant to breast cancer
We tackled the challenge of detecting sentinel lymph node (SLN) metastasis in breast cancer, particularly focusing on cases with epidermal growth factor receptor (EGFR) positivity. By utilizing a specific model that involved the MDA-MB-468 breast cancer cell line, we tested the effectiveness of Cu-labeled cetuximab, a protein treatment, through a method known as immuno-positron emission tomography (immuno-PET).
In our experiments, we introduced [Cu]Cu-PCTA-cetuximab into the body either intravenously or via local injections around the tumor. Following this, we conducted imaging with PET to gauge how well this treatment could pinpoint the presence of cancer in SLNs. Importantly, our findings indicated that the intravenously administered Cu-labeled cetuximab was particularly effective in diagnosing SLN metastasis.
Furthermore, the method showed promise for better detection of cancerous spread compared to conventional approaches. Although we still need more research, the idea of applying this treatment through local injections appears beneficial, highlighting its focused accumulation in the lymph nodes.
In our experiments, we introduced [Cu]Cu-PCTA-cetuximab into the body either intravenously or via local injections around the tumor. Following this, we conducted imaging with PET to gauge how well this treatment could pinpoint the presence of cancer in SLNs. Importantly, our findings indicated that the intravenously administered Cu-labeled cetuximab was particularly effective in diagnosing SLN metastasis.
Furthermore, the method showed promise for better detection of cancerous spread compared to conventional approaches. Although we still need more research, the idea of applying this treatment through local injections appears beneficial, highlighting its focused accumulation in the lymph nodes.
Read More
9
Gracillin shows promise against cancer
Gracillin suppresses cancer progression through inducing Merlin/LATS protein-protein interaction and activating Hippo signaling pathway.
High relevance to breast cancer
We investigated the potential of gracillin, a natural saponin derived from herbs, as a treatment for breast cancer and other malignancies. In our research, gracillin demonstrated significant ability to slow down the growth of breast cancer cells, liver cancer cells, and glioblastoma cells. The experiments showed that gracillin effectively inhibited cell proliferation, migration, and invasion at concentrations around 1 μM.
This natural compound works by activating the Hippo signaling pathway in a unique way. We found that gracillin enhances the interaction between two proteins, Merlin and LATS, which is crucial for activating this pathway. Disrupting this interaction with a specific peptide negated gracillin's anticancer effects, highlighting its importance in our findings.
Additionally, we conducted tests on nude mice with breast cancer tumors. The administration of gracillin resulted in a noticeable reduction in tumor growth, correlating with the induced protein interactions and the activated Hippo signaling. Our results underscore the promise of gracillin as a potential therapeutic agent in cancer treatment, particularly through its novel approach to activating crucial signaling pathways.
This natural compound works by activating the Hippo signaling pathway in a unique way. We found that gracillin enhances the interaction between two proteins, Merlin and LATS, which is crucial for activating this pathway. Disrupting this interaction with a specific peptide negated gracillin's anticancer effects, highlighting its importance in our findings.
Additionally, we conducted tests on nude mice with breast cancer tumors. The administration of gracillin resulted in a noticeable reduction in tumor growth, correlating with the induced protein interactions and the activated Hippo signaling. Our results underscore the promise of gracillin as a potential therapeutic agent in cancer treatment, particularly through its novel approach to activating crucial signaling pathways.
Read More
9
Synergistic effect in breast cancer
Synergetic effect of doxorubicin and avenanthramide C on VDAC2/MTCH1 mitochondrial axis in breast cancer cells.
Combination therapy shows potential
We evaluated how combining doxorubicin (DOX), a common chemotherapy drug, with avenanthramide C (AVC), a natural compound, could enhance the effectiveness of breast cancer treatment. Utilizing MCF-7 breast cancer cells, we treated them with varying doses of both DOX and AVC to observe their combined effect on cell death, or apoptosis.
Our results showed that the DOX-AVC combination significantly increased the cytotoxic effects compared to using DOX alone, reducing the amount needed for effective treatment. We noted that this synergy appeared to enhance apoptosis rates by a remarkable 76% in treated cells. Additionally, we discovered substantial increases in two key mitochondrial proteins, VDAC2 and MTCH1, linked to the apoptosis process, which may explain how the combination works at a cellular level.
This research highlights a promising strategy not only for improving breast cancer therapies but also for potentially minimizing some common side effects associated with chemotherapy. We believe that further studies in pre-clinical models could pave the way for developing safer, more effective treatments for patients.
Our results showed that the DOX-AVC combination significantly increased the cytotoxic effects compared to using DOX alone, reducing the amount needed for effective treatment. We noted that this synergy appeared to enhance apoptosis rates by a remarkable 76% in treated cells. Additionally, we discovered substantial increases in two key mitochondrial proteins, VDAC2 and MTCH1, linked to the apoptosis process, which may explain how the combination works at a cellular level.
This research highlights a promising strategy not only for improving breast cancer therapies but also for potentially minimizing some common side effects associated with chemotherapy. We believe that further studies in pre-clinical models could pave the way for developing safer, more effective treatments for patients.
Read More
9
MA242 shows promise against breast cancer
Dual inhibitor of MDM2 and NFAT1 for experimental therapy of breast cancer: and anticancer activities and newly discovered effects on cancer metabolic pathways.
High relevance to breast cancer treatment
We explored how MA242, a dual inhibitor targeting MDM2 and NFAT1, could change the game in treating breast cancer. Our study used a variety of breast cancer cell lines with different p53 backgrounds and involved advanced models to see the true impact of this new treatment.
The results were promising. We observed that MA242 effectively reduced cell viability and triggered apoptosis, or programmed cell death, in breast cancer cells—regardless of whether they had the p53 protein. This means it might be effective even in cases where traditional therapies fall short.
Furthermore, we found that MA242 disrupts important metabolic processes within cancer cells, particularly around nicotinamide and nucleotide metabolism, while also increasing oxidative stress. In animal models, it successfully inhibited tumor growth linked to MDM2 expression without harmful side effects, which is a significant advantage.
Overall, our findings suggest that MA242 holds great potential as a treatment option for aggressive breast cancers by modulating cancer metabolism. We believe this dual approach could lead to more effective therapies, especially for patients who have limited options today.
The results were promising. We observed that MA242 effectively reduced cell viability and triggered apoptosis, or programmed cell death, in breast cancer cells—regardless of whether they had the p53 protein. This means it might be effective even in cases where traditional therapies fall short.
Furthermore, we found that MA242 disrupts important metabolic processes within cancer cells, particularly around nicotinamide and nucleotide metabolism, while also increasing oxidative stress. In animal models, it successfully inhibited tumor growth linked to MDM2 expression without harmful side effects, which is a significant advantage.
Overall, our findings suggest that MA242 holds great potential as a treatment option for aggressive breast cancers by modulating cancer metabolism. We believe this dual approach could lead to more effective therapies, especially for patients who have limited options today.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.4
7.5
Protein benefits highlight
#1 product on the market! I'm a Certified Master Trainer with over 20 years of experience, and I use Whey Protein Isolate daily. Specifically, I swear by Optimum Nutrition 100% Whey Gold Standard because it offers great protein concentration and minimal lactose. It's crucial for muscle and immune health, and it even helps reduce the risk of breast cancer in women. The taste is phenomenal, and it mixes well, ensuring I get the nutrition I need to stay fit and healthy.
Read More
